Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 22804102)

1.

Potential role of non-insulin adjunct therapy in Type 1 diabetes.

George P, McCrimmon RJ.

Diabet Med. 2013 Feb;30(2):179-88. doi: 10.1111/j.1464-5491.2012.03744.x. Review.

PMID:
22804102
2.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.

PMID:
15498087
5.

What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?

Zenari L, Marangoni A.

Diabetes Obes Metab. 2013 Sep;15 Suppl 2:17-25. doi: 10.1111/dom.12143. Review.

PMID:
24034516
6.

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Scheen AJ.

Diabetes Metab. 2012 Apr;38(2):89-101. doi: 10.1016/j.diabet.2011.11.001. Epub 2011 Dec 22. Review.

7.

Use of non-insulin therapies for type 1 diabetes.

Garg SK, Michels AW, Shah VN.

Diabetes Technol Ther. 2013 Nov;15(11):901-8. doi: 10.1089/dia.2013.0281. Epub 2013 Oct 16. Review. No abstract available.

PMID:
24131372
8.

Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.

Lee NJ, Norris SL, Thakurta S.

Ann Fam Med. 2010 Nov-Dec;8(6):542-9. doi: 10.1370/afm.1174. Review.

9.

Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.

Vora J, Bain SC, Damci T, Dzida G, Hollander P, Meneghini LF, Ross SA.

Diabetes Metab. 2013 Feb;39(1):6-15. doi: 10.1016/j.diabet.2012.08.002. Epub 2012 Sep 27. Review.

10.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
11.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

12.

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Weyer C, Maggs DG, Young AA, Kolterman OG.

Curr Pharm Des. 2001 Sep;7(14):1353-73. Review. Erratum in: Curr Pharm Des 2001 Dec;7(18):1967.

PMID:
11472273
13.

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

Ryan GJ, Jobe LJ, Martin R.

Clin Ther. 2005 Oct;27(10):1500-12. Review.

PMID:
16330288
15.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.

16.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
17.

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Derosa G, Maffioli P.

Diabetes Technol Ther. 2012 Apr;14(4):350-64. doi: 10.1089/dia.2011.0204. Epub 2012 Feb 10. Review.

PMID:
22324384
18.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Hermansen K, Mortensen LS.

Drug Saf. 2007;30(12):1127-42. Review.

PMID:
18035865
19.

[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].

Gabbay Mde A.

Arq Bras Endocrinol Metabol. 2008 Mar;52(2):279-87. Review. Portuguese.

20.

Adjunct therapy for type 1 diabetes mellitus.

Lebovitz HE.

Nat Rev Endocrinol. 2010 Jun;6(6):326-34. doi: 10.1038/nrendo.2010.49. Epub 2010 Apr 20. Review.

PMID:
20404854
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk